Atrial fibrillation (AF) and atrial flutter are often studied together, but rarely reported separately, and the efficacy of anti-arrhythmic medication for atrial flutter has been sparsely investigated. As prolonged treatment with anti-arrhythmic medication is associated with severe adverse effects, 1 there has been an increasing use of radiofrequency ablation.
flutter ablation are sparse 3 and some observational studies have revealed a similar or even higher long-term mortality risk compared with AF ablation procedures.
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The aim of this study was to follow patients from their first ablation procedure for either atrial flutter or AF to give a detailed description of the prognosis of death, incidence of renewed arrhythmia (ablation or pacemaker implementation) and heart failure. Patients Registry. 8 The Danish National Prescription Registry 9 contains information on dispensed medication redeemed from Danish pharmacies since 1994, with date of purchase, dosage, amount, and product identification using the Anatomical Therapeutic Chemical (ATC) Classification codes. For a list of ICD-10, SKS and ATC codes used for this study, the reader is referred to Data S1. The Danish
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Health Data Agency provided the data for this study.
The study population consists of Danish patients with either an incident atrial flutter or AF ablation procedure code (BFFB03 and BFFB04 respectively), between 1 January 2000 and 31 December 2016. Patients with a prior ICD-10 code for congenital heart diseases, pacemaker, valvular heart disease, heart failure, ischaemic heart disease and/or thromboembolism were excluded from the study ( Figure   S1 ) as to focus on a fairly healthy population in terms of severe heart disease at time of ablation. Time of ablation defined study cohort entry.
During follow-up, we looked for procedure codes for renewed arrhythmia intervention in the Danish National Patient Registry.
Renewed arrhythmia included a new ablation procedure, including atrial flutter or AF ablation, and/or pacemaker implantation, which are reported both combined and separately. Eventually, hospital discharge codes for heart failure were identified from the same registry. Information on patient vital status was obtained from the Danish Civil Registration system.
Patient comorbidity at study entry was identified by prior hospital discharge codes, procedure codes and prescription information with focus on cardiovascular risk factors and potential confounders for arrhythmia or heart failure. A redeemed prescription within 1 year before study entry was considered as indication of treatment.
Anti-arrhythmic medications included amiodarone, digoxin, verapamil, sotalol, flecainide and dronedarone. Beta-blockers and anticoagulant treatment were also identified.
The study population was described at baseline by proportions for binary covariates and with means and standard deviations for non-binary covariates. Standardised differences were used to describe baseline differences between the two patient groups. 10 Overall survival and disease-free survival in terms of no renewed arrhythmia, no diagnose of heart failure, or death were described by Kaplan-Meier survival curves. The cause-specific incidence of renewed arrhythmia or heart failure was obtained using the AalenJohansen estimator 11 for the cumulative incidence rates under competing risk of death. Mortality and morbidity was quantified by event rates as number of events divided by person-years at risk stratified on ablation group. A semi-Markov transition model ( Figure 1 ) 11 was used to compare event rates between ablation groups for disease progression during follow-up. The model included the following states: initial ablation, renewed arrhythmia, heart failure and death.
Time in each state was used as timescale for all analyses, that is, we assume reset of time at each state shift.
What's known
• Atrial flutter ablation is now considered a safe and in some circumstances a curative treatment, superior to treatment with anti-arrhythmic medications.
• Studies on long-term follow-up after atrial flutter ablation are sparse and some observational studies have demonstrated a similar or even higher long-term mortality risk compared with AF ablation procedures.
What's new
• Patients undergoing atrial flutter ablation are associated with a higher mortality compared with patients undergoing atrial fibrillation ablation.
• Atrial flutter ablation patients were observed with a higher risk of heart failure, and of renewed atrial flutter ablation, and pacemaker implantation.
• Renewed arrhythmia management among atrial flutter only were associated with a trend for a higher risk of heart failure.
F I G U R E 1 Graphical representation of the transition model. Arrows indicate the allowed transitions from initial ablation through renewed arrhythmia (atrial flutter, atrial fibrillation ablation, or pacemaker implantation) and heart failure to death
The hazard functions of all transitions were modelled jointly using the parametric model of This model uses a cubic spline to represent the underlying baseline function, which allows inclusion of non-proportional effects and detailed summary statistics of the model describing the expected prognosis of the ablation patients.
Hazard ratios were adjusted for potential confounding by baseline differences using the following variables: age (continuous, restricted cubic spline), sex (binary), hypertension (binary) and diabetes (binary).
Non-proportionality between ablation groups on transition hazards were tested using likelihood ratio tests and only found significant for the transition between initial state and renewed arrhythmia. The AF ablation group was used as reference for all analyses. A follow-up of 10 years was used for the main analyses; results for 5 years follow-up are given in Data S1. As a supplementary analysis, we present the time courses and 10-year status of the probability of being in each state, the accumulated time (length of stay) in each state for each ablation group as well as the difference between ablation groups. The uncertainty of these statistics was represented by point wise 95%
confidence intervals estimated by simulation. 12 Throughout the anal- 
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The study population consisted of 2,004 and 3,803 patients with an incident atrial flutter or AF ablation procedure, respectively. A flow chart of the study population is shown in Figure S1 . Average followup was 5.5 years and approximately 16% had more than 10 years of potential follow-up. Baseline characteristics are shown in Table 1 .
The study population was mainly male (>70%) with a median age about 60 years. More than 99% had a hospital discharge diagnose for atrial flutter or AF before the ablation procedure and more than 60% with a specific diagnose in accordance with the type of ablation.
Up to 30% had, however, an unspecified atrial flutter or AF diagnose only ( Table 1 ). The predominant comorbidity was hypertension, observed in 40% of both groups, whereas diabetes or cancer was observed in less than 10%. In general, the proportions with comorbidity were slightly higher in the atrial flutter group compared with the AF group. In both arrhythmia groups the majority (>70%) were treated with a beta-blocker and received oral anticoagulant treatment within 1 year before ablation. The proportions of patients with a prescription of anti-arrhythmic medication prescription were 39%
and 58% for the atrial flutter and AF ablation groups, respectively. flutter was about 50% and 40% for AF (Figure 2 ). In the multi-state analysis, this corresponds to continued stay in the initial state. Based on the multi-state model analysis, the adjusted event-free prognosis 10 years after ablation was not significantly different between ablation groups. ( Figure S3 , Table S2 ). This accounted to an expected 6.6 years being event-free following the initial atrial flutter ablation, which was 0.5 (95% CI 0.3-0.8) years longer than a comparable patient in the AF ablation group (Table S2) .
Crude all-cause mortality in atrial flutter was about 15% after 10 years ( Figure 2 ) and observed with a rate of 1.56 per 100 personyears, which was significantly higher compared with the AF group (HR 1.80, 95% CI 1.39-2.35) ( Table 2) . This difference between ablation groups was increased when focusing on mortality without observed indication of disease progression in terms of renewed ablation or heart failure (T1 in Figure 1 ) with HR 3.00 (95% CI 2.14-4.20) ( Table 2 ). This was also observed after renewed arrhythmia (T4) (HR 1.98, 95% CI 1.24-3.15) and/or disease progression given by heart failure (T6) (HR 1.91, 95% CI 1.07-3.39). The 10 year survival probability of a healthy male patient aged 60 years included due to atrial flutter ablation was 87.6% being 7.7% point (95% CI 5.5%-9.9%) lower than a comparable AF ablation patient. In terms of life-span this corresponded to 4.6 months (0.38 years) shorter life for the atrial flutter patient ( Figure S3 , Table S2 ).
The incidence of renewed arrhythmia (T2 in Figure 1 Table 2 ). The intensity of renewed ablation vary during the first 1.5 years after initial AF ablation ( Figure 2 ) with a short period with a low rate of renewed ablation followed by a period with a high rate. For the atrial flutter group, the cumulative incidence increases linearly in the same period. After this, F I G U R E 2 Crude survival and cumulative incidence curves. Event-free survival in terms of no further arrhythmia management, no diagnosis of heart failure, or death CI 0.36-0.46), whereas, a renewed flutter ablation procedure was more likely (HR 2.42, 95% CI 2.02-2.91) ( Table 2 ). The crude rates of atrial flutter and AF ablation for the atrial flutter group were 3.20 and 3.77 respectively, whereas in the AF group the crude rate of renewed AF ablation was 12.1, being 10-fold the rate of atrial flutter ablation. Rates of pacemaker implantations were higher among atrial flutter patients than in AF (Table 2) . In both groups, His ablation rates where low.
The crude overall incidence of heart failure was higher among atrial flutter compared with the AF group (Figure 2) . The transition rates to heart failure were higher for atrial flutter, both from initial ablation (T3 in Figure 1 ) (HR 1.48, 95% CI 1.08-2.03) and from arrhythmia management (T5 in Figure 1 ) (HR 1.98, 95% CI
1.33-2.94).
In Figure 3 , the crude cumulative incidence functions of heart failure and death are plotted within ablation group with focus on possible renewed ablation, respectively T5 vs T3 and T4 vs T1
( Figure 1 ). The outcome of heart failure was increased in the atrial flutter group after renewed ablation compared with rate after the initial ablation (HR 1.41, 95% CI 0.98-2.02) ( Figure 3 ).
Restricting the follow-up period to 5 years did not materially alter the conclusions (Tables S2-S4 ).
| D ISCUSS I ON
In this study, our principal finding was a significantly higher allcause mortality risk after an atrial flutter ablation procedure compared with an AF ablation procedure, even after adjustment for well-known general mortality risk factors such as age, sex, hypertension, and diabetes mellitus. This difference remained higher for patients with no subsequent renewed ablation or identified heart failure. Second, overall atrial flutter patients were more likely being free of further disease progression or need for renewed ablation.
The rate of renewed AF ablation among AF ablation patients was high and contributed to this apparent difference between the atrial flutter and AF patient groups. The atrial flutter group had significantly higher rates of pacemaker implantations compared with the AF group. Heart failure was more frequently observed among atrial flutter irrespective intermediate renewed ablation. Figure S2 .
TA B L E 2 Transition event rates per 100 person-years (number of events) and adjusted hazard ratios (95% confidence intervals) for outcomes atrial flutter ablation with atrial fibrillation ablation as reference with 10 y follow-up
The mortality rate among patients who underwent atrial flutter ablation in our study was lower than reported by Seara et al who found a mortality rate of 2.2 per 100 persons-year after an atrial flutter ablation procedure 13 and in the observational study by
Lelorier et al 5 where the mortality rate was 2.91 per 100 patientyears. The lower mortality rate might be due to the intentional inclusion of a generally healthier population (less hypertension, chronic obstructive pulmonary disease, diabetes etc.) as we employed more stringent exclusion criteria by excluding patients with prior stroke, ischaemic heart disease and/or heart failure.
Catheter ablation for atrial flutter is generally considered a safe and effective procedure; in a meta-analysis of cavotricuspid ablations, procedure-related complications were rare (2.6%) and primarily related to peripheral vascular complications, pulmonary embolism, complete heart block, myocardial infarction, sustained ventricular arrhythmias and pericardial effusions.
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We observed a higher rate of pacemaker implantation in the atrial flutter ablation group compared with the AF ablation group (HR 1.42, 95% CI 1.13-1.79), and it could be speculated that procedure-related complications, eg, high degree AV-block, might confer a higher mortality risk. Late pacemaker related complications, for example, pocket infections, endocarditis, and late pericardial effusions, might, however, play a role in the increased long-term mortality among patients who underwent atrial flutter ablation. A more recent Danish study found a 5.8% risk of major complications during the first 6 months following a primary pacemaker implantation. 15 However, infections occurring more than 1 year after primary pacemaker implantation are rare, 1.02 per 1000 pacemaker-years, and altogether F I G U R E 3 Cumulative incidence functions for the outcome Heart failure after initial ablation (T3) and after renewed arrhythmia (T5) by initial ablation type (left panel). Mortality functions for the outcome Death after initial ablation (T1) and after renewed arrhythmia (T4) by initial ablation type (right panel)
TA B L E 3 Transition event rates per 100 person-years (number of events) and adjusted hazard ratios (95% confidence intervals) for outcome after renewed ablation compared with rates after initial ablation within each ablation group with 10 years follow-up it seems unlikely that pacemaker complications should be a driver for the observed increased mortality. 16 However, we cannot rule out undiagnosed or delayed development of complete heart block.
The time course of events as displayed by the survival and cumulative incidence curves (see Figure 2 ) consistently indicate that the differences between the ablation groups do not appear during the first year after initial ablation. Typically, ablation patients are monitored in an outpatient setting for a period and thereafter referred to general practice. Anticoagulant treatment is more likely to be interrupted than among AF patients. 6 Also, AF patients may be monitored more closely, which may explain the higher incidence of further arrhythmia management. Further investigations in these aspects are needed specifically if differences in general practice or hospital contacts may be important drivers.
Development of postablation arrhythmias, predominantly after AF ablation, is well known and varies highly between studies, ranging from 13% to 57.2% 3, 5, 13, [17] [18] [19] and, if undetected, these could lead to tachycardia-induced cardiomyopathy. In our study, only 349 (17.4%)
transitioned to an AF ablation procedure from the atrial flutter group and 296 (14.8%) underwent a repeated atrial flutter procedure which corresponds with other studies. 13 Transition from the renewed arrhythmia state to heart failure or death was more likely among atrial flutter compared with AF (HR 1.98, 95% CI 1.33-2.94 and HR 1.98, 95% CI 1.24-3.15, respectively). Only in the atrial flutter ablation group a nearly significant increase in heart failure was observed after renewed ablation. In all other cases, renewed ablation did not lead to significant changes in heart failure or mortality. These results do not indicate that repeated arrhythmia management should be associated with disease worsening, as renewed arrhythmia was not seen associated with an increase in mortality. The mortality rates were, as mentioned above, increased in both groups after heart failure. Further research is needed to investigate if the higher mortality among atrial flutter patients may be due to higher proportion of patients with undiagnosed and/or untreated heart failure.
There are important limitations to this study, given the observational nature of the design. Most importantly, our study is based on registry data, which leaves open the possibility of residual and unmeasured confounding, and misclassification. In this study, atrial flutter ablation was offered to slightly older patients but any difference in comorbidity was modest (Table 1) . However, not all comorbidities are captured by the health registries, as diagnoses identified in general practice will only be observed indirectly by initiated medical treatment (Danish National Prescription Registry).
Nonetheless, it is likely that these unobserved comorbidities would distribute non-differentially between ablation groups. The general registries lack detailed information leading to the decision of ablation, such as the results of Holter or ECG analyses, there may as such be differences in severity and persistence of arrhythmia.
Using procedure codes for arrhythmia classification the data are considered reliable, as the procedure codes are only given on actual performing the procedure. Misclassification is unlikely as the procedures are quite different, however it must be acknowledged that the initial AF ablation may lead to atypical left atrial flutter being treated with a renewed ablation, which may very likely be coded as an AF ablation. The baseline classification of AF ablation by procedure code is however considered reliable, as atypical left atrial flutter in patients with no cardiac intervention is rare. 20, 21 All patients were required to be on anticoagulant treatment, but we had no information on time in therapeutic range among warfarin users, and the warfarin prescription criteria were based on a strict definition. However, quality of anticoagulant therapy would be expected to be non-differential between patients in the two groups.
We did not have any information on laboratory, anthropometric, or socioeconomic data, and we also did not have detailed information on the specific cause of death.
The study is based on data from the Danish population, which is fairly homogeneous in respect to socioeconomic and ethnic background and with free access to medical counselling and treatment.
Finally, our study indicated heart failure being the most critical condition associated with increased mortality. The Danish registers do unfortunately not provide much detailed information on the severity of heart failure and quality differences between populations may influence the external validity of our results.
In this study, there was a higher mortality risk after atrial flutter ablation procedures compared with patients subjected to AF ablation both overall and when taking further disease progression after initial ablation into account. Patients undergoing an AF ablation were more likely to receive a renewed AF ablation, whereas patients subjected to atrial flutter ablation had higher risk of renewed (non-AF) ablation, heart failure and death. Within the atrial flutter group renewed ablation was associated with a trend towards increased risk of heart failure. If the worse prognosis of atrial flutter patients is indeed due to disease progression then the implication of this study should be a closer clinical follow-up of atrial flutter patients. Further research on this is warranted.
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